PDS Biotech
Princeton, New Jersey, United States · Biotechnology, Health Care, Therapeutics
PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.
Key facts
- Headquarters
- Princeton, New Jersey, United States
- Employees
- 21
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (PDSB)
- Website
- pdsbiotech.com
- Company page
Recent activity at PDS Biotech
- : SEC 8-K (8.01): On October 20, 2026, PDS Biotechnology Corporation updated its corporate presentation deck, providing new information relevant to stakeholders. The revised presentation reflects the latest company initiatives and projections, which are important for current and potential investors. A copy of the updated deck is included as Exhibit 99.1, enhancing transparency and engagement with stakeholders. This update signifies the company's ongoing commitments to inform its shareholders and address market expectations.
- : SEC 8-K (5.02): On October 18, 2026, PDS Biotechnology Corporation reported the resignation of directors Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and Otis Brawley, effective immediately. The resignations were not due to any disagreements with the company. Additionally, on the same day, the Board appointed three new directors—Deborah A. Ramsdell (Class A), John A. Dawson (Class B), and Bruce Wendel (Class C)—to fill the vacancies created by the resignations. Ramsdell, who has extensive experience in biotechnology and currently serves as CEO of Pluvia Biotech, will serve until the 2027 Annual Meeting. Dawson will serve until 2029 and Wendel until 2028. This restructuring significantly impacts the Board's composition and strategic oversight moving forward.
- : SEC 8-K (8.01): On October 6, 2026, PDS Biotechnology Corporation announced a virtual key opinion leader (KOL) event featuring Dr. Jonathan M. Hernandez from the National Cancer Institute. The event will discuss clinical outcomes from the PDS0301 Phase 2 trials focused on advanced liver-associated cancers, particularly the metastatic colorectal cancer (mCRC) cohort. This engagement is significant as it highlights clinical advancements and may impact investor sentiment regarding ongoing cancer therapies. A copy of the press release is included as Exhibit 99.1.
- : SEC 8-K (8.01): On September 22, 2026, PDS Biotechnology Corporation announced through a press release the publication of results from a Phase 2 trial evaluating its HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab. The results were published in the September 17, 2026, issue of JAMA Oncology, detailing a nonrandomized clinical trial titled 'VERSATILE-002'. This publication highlights significant advancements in the treatment of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, potentially impacting the therapeutic landscape in oncology. The ongoing evaluation and findings from the trial could influence future clinical approaches and the company's strategic direction in immunotherapy.
- : SEC 8-K (8.01): On September 21, 2026, PDS Biotechnology Corporation updated its corporate presentation deck, which is significant for stakeholders and investors seeking the latest insights into the company’s strategic direction and business operations. The updated presentation is filed as Exhibit 99.1, providing key information about the company's performance and future plans. This event is important as it may influence investor sentiment and market perception regarding the company's growth potential.
- : PDS Biotechnology Corporation announces the initial closing of up to $22.3 million PIPE financing, raising $11.3 million. The round was led by Nant Capital with participation from current investors.
- : SEC 8-K (5.02): On September 12, 2026, the Board of Directors of the Company appointed Dr. Patrick Soon-Shiong and Mr. James Banaag as new directors, filling vacancies created by the Board's increase from six to eight members. This appointment was made pursuant to the Securities Purchase Agreement dated September 7, 2026, which grants Nant Capital, LLC rights to designate board members as long as they hold at least 15% of the Company's common stock. The initial closing of this agreement occurred on September 14, 2026. Dr. Soon-Shiong is a notable figure in the biotechnology sector, having founded ImmunityBio, Inc. and previously leading multiple pharmaceutical companies, which contributes to the strategic direction of the board.
- : SEC 8-K (1.01): On September 7, 2026, PDS Biotechnology Corporation entered into a Securities Purchase Agreement with certain accredited investors, committing to issue shares of Common Stock and warrants in an unregistered private placement. The initial closing is anticipated on or about September 11, 2026, with gross proceeds projected at approximately $11,550,000. The agreement includes terms where shares and warrants are issued at specific prices, with conditions on ownership limitations. This Strategic financing is aimed at bolstering the company's capital resources for future operations.
- : SEC 8-K (1.01): On August 31, 2026, PDS Biotechnology Corporation entered into a First Amendment to a Promissory Note with YA II PN, Ltd. This Amendment modifies the original Promissory Note issued on June 15, 2026, with a principal amount of $6,000,000. Key changes include the requirement for weekly remittance notices regarding sales proceeds, an extension of the Nasdaq listing deficiency cure period from 75 to 180 days, and mandatory redemption of net cash proceeds from certain financings within five business days. This amendment is crucial for the Company's financial management and compliance with listing requirements.
- : SEC 8-K (5.02):
PDS Biotech funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Post-IPO Equity | $11.3M |
| Aug 2022 | Debt Financing | $35.0M |
Leadership
- Paul, Vice President, Technical Operations & Manufacturing
- Danuta, Head of Human Resources & Facilities Administration
- Stephan Toutain, Chief Operating Officer
- Kirk V. Shepard, Chief Medical Officer
- Lars Boesgaard
Verified email and direct lines for PDS Biotech’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
PDS Biotech files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
PDS Biotech in the news
- PDS Biotechnology Corporation (PDSB) stock price, news, quote and history - Yahoo Finance Singapore (Apr 06, 2019)
- PDS Biotech Appoints Stephan Toutain as Chief Operating Officer - citybiz (May 02, 2024)
- A National Cancer Institute investigator will discuss an experimental treatment for colorectal cancer that spread to the liver. - Stock Titan (Oct 06, 2026)
- PDS Biotechnology Corp. Closes $52M Public Offering - citybiz (Jun 17, 2021)
- A cancer biotech raises $11.3 million. The Los Angeles Times owner joins its board. - Stock Titan (Sep 14, 2026)
- PDS Biotechnology Appoints Sanjay Zaveri as Senior Vice President - citybiz (May 18, 2022)
- PDS Biotech Completes $35M Financing Agreement Led By Horizon Technology Finance - citybiz (Aug 24, 2022)
- PDS Biotechnology Corporation (PDSB) Stock Price, News, Quote & History - Yahoo! Finance Canada (Apr 21, 2019)
Companies similar to PDS Biotech
- CytoDyn · Biotechnology, Health Care, Therapeutics
- Kynexis · Biotechnology, Health Care, Therapeutics
- LAVA Therapeutics · Biotechnology, Health Care, Therapeutics
- Waypoint Bio · Biotechnology, Health Care, Therapeutics
- NRx Pharmaceuticals · Biotechnology, Health Care, Therapeutics
About PDS Biotech: questions and answers
What does PDS Biotech do?
PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.
Where is PDS Biotech headquartered?
PDS Biotech is headquartered in Princeton, New Jersey, United States.
How many employees does PDS Biotech have?
PDS Biotech has about 21 employees.
Has PDS Biotech raised funding?
Yes. Fundz has recorded 2 funding events for PDS Biotech. The most recent, Post-IPO Equity of $11.3M, was in Sep 2026.
Who leads PDS Biotech?
Paul is a Vice President, Technical Operations & Manufacturing at PDS Biotech.
What is the latest news on PDS Biotech?
On Oct 20, 2026, SEC 8-K (8.01): On October 20, 2026, PDS Biotechnology Corporation updated its corporate presentation deck, providing new information relevant to stakeholders. The revised presentation reflects the latest company initiatives and projections, which are important for current and potential investors. A
Is PDS Biotech a public company?
Yes. PDS Biotech is publicly traded under the ticker PDSB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy